2007
DOI: 10.1038/ncb1672
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Epidermal growth factor (EGF) receptor (EGFR) signalling is implicated in tumour invasion and metastasis. However, whether there are EGFR signalling pathways specifically used for tumour invasion still remains elusive. Overexpression of Arf6 and its effector, AMAP1, correlates with and is crucial for the invasive phenotypes of different breast cancer cells. Here we identify the mechanism by which Arf6 is activated to induce tumour invasion. We found that GEP100/BRAG2, a guanine nucleotide exchanging factor (GE… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

13
299
2
3

Year Published

2009
2009
2023
2023

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 200 publications
(317 citation statements)
references
References 25 publications
13
299
2
3
Order By: Relevance
“…Sabe and colleagues reported that BRAG2 is recruited to the phosphorylated EGF receptor by direct association of its PH domain with phosphorylated tyrosine residues 1068/1086 in the EGFR cytoplasmic tail. 7 In contrast, Kornau and colleagues demonstrated a direct interaction between BRAG2 and a non-phosphorylated tyrosine (Y876) in the cytoplasmic domain of the GluA2 subunit of neuronal AMPA receptors that required the PH domain. 8 In this case, phosphorylation of Y876 actually inhibited BRAG2 binding.…”
Section: Characteristics Of the Brag Subfamilymentioning
confidence: 99%
“…Sabe and colleagues reported that BRAG2 is recruited to the phosphorylated EGF receptor by direct association of its PH domain with phosphorylated tyrosine residues 1068/1086 in the EGFR cytoplasmic tail. 7 In contrast, Kornau and colleagues demonstrated a direct interaction between BRAG2 and a non-phosphorylated tyrosine (Y876) in the cytoplasmic domain of the GluA2 subunit of neuronal AMPA receptors that required the PH domain. 8 In this case, phosphorylation of Y876 actually inhibited BRAG2 binding.…”
Section: Characteristics Of the Brag Subfamilymentioning
confidence: 99%
“…Brag2 (GEP100/IQSEC1) is a GEF activating the small ArfGTPases Arf4, Arf5 and Arf6 [33,48] and is expressed in EC [20,45]. Brag2 was found to promote the invasive activity of breast cancer cells [34] and myoblast fusion [11,37]. Furthermore, Brag2 was shown to be involved in trafficking processes such as the endocytosis of synaptic AMPA-receptors, E-Cadherin recycling, and phagocytosis of monocytes [21,46,47].…”
Section: Introductionmentioning
confidence: 99%
“…Nous avons d'abord dûment noté que plus du tiers des sujets parkinsoniens étaient affligés d'un TCSP [9]. Nous avons ensuite observé que seuls les sujets parkinsoniens victimes d'un TCSP présentaient un ralentissement de l'activité EEG à l'éveil et une atteinte des fonctions cognitives détectée lors des tests neuropsychologiques [10,11]. Les sujets parkinsoniens non affectés de TCSP ne présentaient ni anomalies de l'EEG, ni atteintes des fonctions cognitives.…”
Section: Tcsp Et Maladie De Parkinsonunclassified
“…Ainsi, la détection des facteurs d'échanges responsables de l'activation d'ARF1 est primordiale. Bien qu'au total on dénombre 15 ARF GEF (guanine nucleotide exchange factor) et 24 ARF GAP (GTPase activating protein) [8,9], de récents résultats suggèrent qu'ARF6 est activée par le recrutement de BRAG2/ GEP100 au niveau de l'EGFR [10]. Cette ARF GEF interagit directement avec les résidus tyrosine 1068/1086 et, par la suite, permet la liaison du GTP sur ARF6.…”
Section: Un Potentiel Thérapeutique Intéressantunclassified